News

ILTOO PHARMA SAS announces the initiation of Managed Access Programs for the compassionate treatment of patients afflicted with Amyotrophic Lateral Sclerosis (ALS) with ILT-101, the company’s lead drug.

Today, we come together to raise awareness and show solidarity for a cause that knows no borders – Amyotrophic Lateral Sclerosis (ALS)/ Motor Neurone Disease (MND).

ILTOO Pharma SAS today announced that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation (ODD) status for ILT-101, the company’s lead drug for the treatment of amyotrophic lateral sclerosis (ALS).

ILTOO Pharma SAS today announced the signing of Licence Agreement for the development of low dose interleukin-2 as a potential treatment for Amyotrophic Lateral Sclerosis

ILTOO Pharma SAS today announced the results of MIROCALS, a Phase IIb trial in amyotrophic lateral sclerosis (ALS) using low-dose Interleukine-2 (IL-2LD), which were presented by Dr. Gilbert Bensimon at the International Symposium on ALS / Motor Neuron Diseases.

ILTOO Pharma SAS, a clinical stage biotech company in Paris France, today announced that the results of MIROCALS, a Phase IIb trial in amyotrophic lateral sclerosis (ALS) using low-dose Interleukine-2 (LD-IL2), will be presented at the 2022 International Symposium on ALS/MND to be held on 6-9 December. Details of the Symposium can be found here:  https://symposium.mndassociation.org

ILTOO Pharma to sponsor and attend “The Promise of Interleukin-2” Symposium to be held at Sorbonne University in Paris from 14 – 17 September 2022 led by Dr David Klatzmann, a leader in the field of autoimmune disease research.

Jeff’s career has focused on technology commercialisation and management of technology related businesses with a deep science component. His work has spanned from working with scientists from the Jet Propulsion Laboratory of NASA to nanoscale technologies for the high volume semiconductor manufacturing industry. Jeff joins the company at a critical transition point to commercial operation.

José Achache is the CEO of ALTYN, a consulting firm in Geneva Switzerland specialising in deep technologies involving space and scientific concerns.  José is an entrepreneur at heart and is an investor and Board member of several companies.  His leadership will lead the company through its next phase and into the future.  

ILTOO Pharma to attend “The Promise of Interleukin-2” webinar – Wednesday June 15, from 6.00 – 7.30 pm

ILTOO Pharma to attend 3rd Treg Directed Therapies Summit and participate as speaker to the “Ensuring Maintenance of Treg Cells for Enhanced Therapeutic Effect” Thursday, 20 May 2021 4:00 pm EST

ILTOO Pharma has promoted  David Leroux to lead the company’s Clinical Operations. David’s background includes more than 20 years of experience in clinical development in the pharma/biotech industry. He has over the years managed international teams, whether clinical or cross-functional to drive small, first-in-human studies to large clinical phase 3 trials.

ILTOO Pharma is pleased to attend and present ILT-101 development progress at the inaugural Treg Summit 2018 from 22-24 May in Boston.

Dominique Batéjat, 15+ years of experience in the biotech industry joins ILTOO Pharma team. Dominique Batéjat strongly contributed to development of VAC-3S vaccine for the treatment of HIV within InnaVirVax. She previously worked in academia (INSERM, CEA) and other biotech companies namely Cellectis and Nautilus Pharma.

ILTOO will attend SACHS Forum and participate as a speaker to the “Autoimmune and inflammatory diseases” panel.